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Summary A two phase radioimmunotherapy based on bispecific MAbs in which one arm recognises a
tumour antigen and the other a radiolabelled chelate, may prove more effective in the treatment of carcinomas
than currently available immunotherapies. To establish this system we first showed that penetration into
human carcinoma xenografts as well as long term retention of intact MAb outside the carcinoma cells can be
obtained. Epitope saturation was not obtained however, despite the large MAb doses injected i.v. for 10 days.
We then generated hybridomas producing high avidity anti-metal chelate MAbs (anti-DTPA-Y). These
hybridomas were fused with hybridomas producing MAbs against CEA or GIT-mucin, and stable bispecific
MAb producing quadromas were obtained. For the anti-GIT-mucin x anti-chelate MAb a purification proce-
dure based on double anti-idiotype affinity chromatography was shown to result in greater than 95% pure
bispecific immunoreactive MAb. Comparative in vivo stability studies profiled DTPA-Y as the chelate of
choice for in vivo application.
Immunoscintigraphy using Tc-99m-labelled MAbs (Schwarz
& Steinstraesser, 1987) is becoming a routine diagnostic
method for the in vivo detection of tumours (Baum et al.,
1988, 1989; Kroiss et al., 1989; Lind et al., 1989) and
inflammatory processes (Joseph et al., 1987, 1988a, b; Becker
et al., 1989). In contrast, radioimmunotherapy using MAbs
tagged with 1-131 or Y-90 has not been accepted as a treat-
ment modality in oncology despite a few encouraging early
reports (Epenetos & Kosmas, 1989; Epenetos, 1987). This is
mainly due to the small amounts of radiolabelled MAbs
bound to the tumour site and the unfavourable whole body
distribution and metabolisation of intact immunoglobulins or
their fragments (Thomas et al., 1989). Given this situation,
the presence of a radioactive a- or ,B-emitter or a toxic drug
coupled to the MAb is likely to result in extensive destruc-
tion of non-tumour tissues.
It may be possible to circumvent these problems using a
two phase approach (Bagshawe, 1987; Bagshawe et al., 1988;
Hnatowich et al., 1987, 1989; Senter et al., 1988; Le Doussal
et al., 1989; Goodwin et al., 1988) a procedure pioneered in
the 70s by Philpott et al. (1973), which has recently become
the focal point of renewed interest. This approach involves a
long term non-toxic targeting phase with a modified MAb
and a second short term binding of a toxic molecule to the
MAb or site specific activation of a small hydrophilic pro-
drug.
In this report we show that it is possible to target signi-
ficant amounts of MAb to human colon and pancreatic
carcinoma xenografts and to retain the MAb for many days
at the tumour site. If such an MAb would have two arms
with different specificities, one against the tumour, the second
against a small hydrophilic metal chelate, it should be possi-
ble to target a quickly-distributing and penetrating chelate
very efficiently to the tumour. Because of its short plasma
half life and its complete extracellular distribution, a mole-
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cule like DTPA-Y-90 should not harm the normal tissue, but
would hopefully be retained at the tumour by the anti-DTPA
arm of the bispecific MAb.
This paper reports the isolation of high affinity MAbs
directed against DTPA-Y-90 and the production of bispecific
antitumour x anti-DTPA-Y-90 MAbs which should allow us
to optimise the conditions for two phase radioimmuno-
therapy.
Materials and methods
Immunohistochemical investigations
Thin sections (6ttm) from cryopreserved human tumour
xenografts were investigated using the highly sensitive
APAAP-technique (Cordell et al., 1984) without any fixation.
Tumourpercolation and saturation studies
Human colon carcinoma (CoCa4) bearing nude mice (three
animals/group) were injected i.v. with 250tLg of MAbs
BW 431, BW 494 or BW 227 (Bosslet et al., 1986, 1988a)
each day for 10 consecutive days. Tumours were resected at
various days after the final injection and processed for
immunohistochemical investigations.
Production ofDTPA-specific MAb
As immunogen, 19 moles of SCN-benzyl-DTPA were coup-
led to 1 mole of human serum albumin (HSA-benzyl-DTPA)
(Brechbiel et al., 1986). Immunogen was incubated with a
100-fold molar excess of Y-89 for 2 h at RT to saturate
DTPA with Y. Free Y was removed by Sephadex G-25
column chromatography. Groups of 5 Balb/c mice were
injected s.c. at day 0 with 25pg of HSA-benzyl-DTPA-Y
complex mixed with an equal amount of complete Freunds
adjuvant (CFA). At days 7 and 14 the animals received the
same dose of immunogen mixed with incomplete Freunds
adjuvant (IFA). One week later at day 21 immunogen was
diluted in PBS and given i.p. Fusion was performed at day
37 (Kohler & Milstein, 1975) using the SP20/Ag4 myeloma
cells (Shulman et al., 1978) as a fusion partner.
Screening ofhydridomas
Hybridoma supernatants were screened for the presence of
anti-HSA-benzyl-DTPA-Y MAb using an ELISA system in
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which the immunogen was attached to the solid phase (50 ng
well-') of round bottom polystyrol microtitre plates (Fa.
Nunc). Bound MAb was detected using an alkaline phos-
phatase labelled goat anti-mouse Ig antibody combined with
the alcohol dehydrogenase-diaphorase amplification system
(Stanley et al., 1985).
MAb purification
Hybridomas were cultured in serum free Iscoves medium and
MAb was purified from the supernatants according to Ey et
al. (1978).
Competition ELISA
Purified MAb was incubated with increasing concentrations
of DTPA-Y or other chelates for 1 h at RT. These mixtures
were added to HSA-benzyl-DTPA-Y coated round bottom
polystyrol plates. The efficiency of MAb-chelate interaction
was calculated from the molar excess of chelate leading to
50% inhibition of binding to the solid phase immunogen
(IC50 value).
Introduction ofgenetic markers
Hybridomas 431 and 494 (HGPRT+) were selected for
HGPRT deficiency (HGPRT-) by culturing them for several
weeks in increasing concentrations of TG. HAT sensitivity
was reached at 100itg TGml-' for both cells. The TK+
hybridoma 2050/174 was selected for TK sensitivity by cul-
turing it for several weeks in increasing concentrations of
BrdU. HAT sensitivity was obtained at 1000fg BrdU ml-'.
Quadromaproduction
The HGPRT- hybridomas 431 and 494 were each fused with
the TK- hybridoma 2050/174 at a 1:1 ratio. Growing quad-
romas were selected in HAT medium.
ELISAfor detection ofbispecific MAb
To each individual well of a polystyrol round bottom plate
coated with 50 ng HSA-benzyl-DTPA-Y per well, 50;1l of
quadroma supernatant was added and incubated for 30' at
RT. After 3 x washing, 50jA of biotinylated anti-idiotypic
MAb selective for MAb BW 431 (MAb BW 2064) or 50gsl of
biotinylated anti-idiotypic MAb selective for MAb BW 494
(MAb BW 705) (Bosslet et al., 1990) was added. After wash-
ing, the amount of bound bispecific MAb was visualised
using the avidin-biotin peroxidase system (Vector, Burling-
name).
Double anti-idiotype chromatography
Anti-idiotypic MAbs (anti-ids) specific for MAb BW 431,
BW 494 and BW 2050/174 were generated as described (Boss-
let et al., 1990). Protein A sepharose purified anti-ids were
covalently coupled to CNBr-activated sepharose at a concen-
tration of 6.5 mg MAb ml-' gel according to the method
described by van Eijk et al. (1976). Ammonium sulfate preci-
pitated and desalted quadroma supernatants were loaded,
with a speed of 1.5 ml min-' onto columns containing 70 ml
of anti-id coupled gel. After extensive washing with PBS,
pH 7.2, specifically bound idiotypic MAb was eluted using
100 mM citrate buffer, pH 2.0, containing 50 g I' sucrose.
The eluated fractions were pooled, neutralised and then load-
ed onto the second anti-id column.
Quantitative binding assay in antigen excess
Increasing amounts of antigen were added to 200 ng of
purified bispecific MAb. Antigen consisted either of formal-
dehyde fixed GIT-mucin expressing pancreatic tumour cell
suspensions or HSA-methyl-benzyl-DTPA-Y coupled to
CNBr activated sepharose gel. After a 4 h incubation at RT
the antigen was spun down and the amount of unbound
MAb in the supernatant was determined using a quantitative
ELISA specific for mouse IgG. The fraction of unbound
MAb detectable in the supernatant in antigen excess repre-
sents the inactive fraction of the purified MAb preparation.
Generation of Y-90 chelate complexes
The commercially available chelates EDTA and DTPA as
well as DOTA (Desreux, 1980), a generous gift of Dr 0.
Gansow, NCI, USA, were complexed with Y-90 (Isocom-
merz, GDR). Briefly, Y-90 was incubated with a 106, 2 x 104
or 2 x 105 molar excess of EDTA, DTPA or DOTA, respec-
tively. Radiochemical purity was determined with silica gel
chromatography using a 10% ammoniumacetate/methanol
solvent mixture (1/1). The EDTA-Y-90 or DTPA-Y-90 com-
plexes contained less than 5%, or less than 2% free Y-90,
respectively. In contrast, the DOTA-Y-90 complex contained
about 50% free Y-90 which was removed by incubation and
centrifugation using a cation-exchange resin (Dowex 1 x 8,
50-100 mesh, H+ form). The final radiochemical purity of
the DOTA-Y-90 complex was better than 95%.
Animal studies
Radiochemical pure EDTA, DTPA or DOTA complexes
with Y-90 were injected i.v. in Wistar rats. Animals were
exsanguinated under ether anaesthesia. Organs were surgi-
cally removed and radioactivity was determined using a well
type Gamma-counter.
Results
Percolation and retention ofi.v. injected anti-CEA and
anti-GIT mucin MAbs in human colon carcinoma xenografts
Groups of nude mice carrying the CoCa4 human tumour
xenograft received 10 high dose MAb infusions as described
in Material and methods. Immunohistochemical investiga-
tions revealed that MAb BW 431 selective for CEA as well as
MAb BW 494 binding to a stomach, pancreas and colon
carcinoma associated GIT-mucin (Bosslet et al., 1986, 1988a)
penetrated and bound to the colon carcinoma tissue (Figure
1, data shown for MAb BW 494). At the end of the injection
period (day 10), MAb BW 494 could be visualised very
efficiently using a rabbit anti-mouse IgG, second antibody
(Figure la). The MAb was located at the membrane of the
tumour cells, in the lumen and in the interstitial space.
Similar results were obtained at day 20 (Figure lb) and
day 30 (Figure Ic) indicating that the MAb BW494 which
had penetrated the tumour, remained there for a long period
of time. Essentially identical data were obtained using the
CEA specific MAb BW431 indicating that penetration and
long term retention of MAbs in human carcinoma xenografts
is in principal possible. MAb BW 227, selective for a myco-
plasma associated epitope, did not bind to the tumour tissue
at any point investigated (Figure Id). Incubation of the
CoCa4 tissue sections with MAb BW 494 prior to addition of
the anti-mouse IgG, second antibody resulted in only mar-
ginally stronger staining (Figure le), indicating that the long
term i.v. injection enabled MAb BW 494 to bind to the
majority of accessible epitopes. To investigate whether the
high dose and long term i.v. injection had saturated all
epitopes, an isotype switch variant detection experiment was
performed. CoCa4 tissue sections from i.v. treated animals
were incubated with MAb BW 494 IgG2., an isotype switch
variant of MAb BW 494 IgG,, (Bosslet et al., 1988b) and the
binding of this variant was visualised using an anti IgG2a
selective second antibody system. An essentially identical
staining reaction was seen (Figure 1f) indicating that epitope
saturation was not obtained despite the high dose and long
term i.v. injection of MAb BW494.BISPECIFIC MABS FOR TWO PHASE IMMUNOTHERAPY 683
Figure 1 Photomicrograph of tissue sections from the CoCa4
human tumour xenograft stained with the APAAP-technique.
a-c, represent tissue from MAb BW 494 treated mice removed at
days 10, 20 or 30 respectively and stained using a goat anti
mouse IgG, second antibody. d, represents tissue from MAb
BW 227 treated mice removed at day 20 and stained as described
above. e, represents tissue from MAb BW 494 treated mice
removed at day 30 and stained by addition of 20 ,gml-I MAb
BW 494 followed by a goat anti mouse IgG, second antibody. f,
represents tissue from mice treated as in e. Staining was by
addition of 20 gLg ml1 of MAb BW 494 IgG, followed by a goat
anti mouse IgG2. second antibody.
Generation ofanti-DTPA-Y MAbs
Having demonstrated that penetration and long term reten-
tion of intact MAbs is possible in human tumour xenografts,
we undertook to produce a bispecific antitumour x anti-
DTPA-Y MAb. Because no high affinity anti-DTPA-Y
MAbs were available (Reardan et al., 1985), we produced
these MAbs ourselves using HSA-benzyl-DTPA-Y as immu-
nogen (see Material and methods). The arising clones were
screened using a direct binding ELISA on HSA-benzyl-
DTPA-Y solid phase or a competition ELISA. Out of 70
clones five were selected and the binding inhibition data for
these clones are presented in Table I. The individual MAbs
showed different strengths of binding to the various chelates.
In contrast to our expectation, DTPA-Y was not the best
inhibitor. From the Y-chelates investigated the EDTA-Y was
the best inhibitor. Some MAbs were also efficiently inhibited
by uncomplexed DTPA or EDTA or their complexes formed
with irrelevant ions. Especially DTPA-In was a very efficient
inhibitor suggesting it for diagnostic purposes. Structurally
related substances like diaminoethan or transaconitic acid
had no significant inhibitory effect, indicating that the MAb-
chelate binding is not simply due to charge or hydrophobic
interactions, but seems to be more complex. Out of the five
MAbs presented in Table I, MAb BW 2050/174 was selected
for further use because of its very efficient binding to EDTA-Y
and DTPA-In as well as its reasonable binding to DTPA-Y.
Construction ofbispecific MAbs
As tumour specific MAbs, MAb BW 431 directed against
CEA (Bosslet et al., 1988a) and MAb BW 494 directed
against the GIT-mucin (Bosslet et al., 1986) were chosen. In
clinical trials both MAbs have been shown to localise colo-
rectal, stomach, and pancreas carcinomas in patients. The
hybridomas 431 and 494 were selected for HGPRT deficiency
and each was fused with hybridoma 2050/174 selected for TK
deficiency (see Material and methods). The quadromas were
selected in HAT medium and screened for the presence of
bispecific MAb using a specifically developed antigen-anti-
idiotype ELISA system (see Materials and methods). Here
the detailed data obtained in the BW 494 x BW 2050/174
system are presented:
Sixty-two quadromas were obtained in the fusion between
hybridoma 494 and 2050/174 and 29 of these produced
bispecific MAbs. Quadroma DF 28/5 was selected because of
the high titre (1:32) of its supernatant in the antigen-anti-
idiotype ELISA as well as its production rate of 20ltg MAb
10-6 cells/24 h. After cloning by limited dilution, 74% of the
clones produced bispecific MAb. Eighty-six percent were
positive after a second round of cloning and after a third
round 95% of the clones secreted >20 tg MAb ml1. This
quadroma remained stable for 30 passages in mass culture.
Using anti-idiotype chromatography with two consecutive
columns bearing either an anti-idiotypic MAb to BW494
and anti-idiotypic MAb to BW 2050/174, bispecific MAb
from quadroma supernatants could be isolated essentially
free from the nine potentially arising non bispecific molecules
(Milstein & Cuello, 1983). This is demonstrated by the results
of a binding assay carried out in antigen excess, in which
increasing amounts of GIT-mucin or HSA-benzyl-DTPA-Y
were incubated with constant amounts of bispecific MAb.
Measurements of unbound MAb indicated that greater than
95% of the preparation consisted of bispecific immunore-
active molecules (Figure 2a,b). After having shown that it is
possible to obtain purified bispecific MAb with greater than
95% immunoreactivity for both arms, we evaluated the in
vivo stability of the Y-90 chelates, the second component
needed for two phase radioimmunotherapy.
In vivo stability of Y-chelates
To investigate the stability of preformed EDTA-Y-90,
DTPA-Y-90 or DOTA-Y-90 chelates in vivo, 850kBq, 400
kBq or 300 kBq of the respective chelates were injected i.v.
into Wistar rats and the bone as well as the bone marrow684 K. BOSSLET et al.
Table I Quantitative competition ELISA: molar excess of chelate to generate 50% binding inhibition (IC50)
Benzyl- Benzyl-
MAb No. DTPA-Y DTPA DTPA-In DTPA-Fe DTPA-Mn DTPA-Cd DTPA-Zn DTPA-Cu DTPA-Pb DTPA-Y DTPA
2050/174 104 103 <102 2.5x 103 102 102 5x 103 5 x 103 103 2.5x 103 103
2050/531 5 x 104 103 103 5 x 103 102 102 5 x 103 5 x 103 5 x 103 >105 2.5 x 103
2050/532 5 x 104 103 n.d. n.d. 102 102 5 x 103 5 x 103 5 X 103 2.5 x 103 2.5 x 103
2050/534 5 x 104 103 <102 103 102 102 5 x 103 5 x 103 5 x 103 5 x 103 103
2050/535 104 102 <102 5 x 103 102 102 103 103 103 103 5 x 102
1.2 Trans-
Diamino- aconitic
MAb No. EDTA-Y EDTA EDTA-In EDTA-Fe EDTA-Mn EDTA-Cd EDTA-Zn EDTA-Cu EDTA-Pb ethan acid
2050/174 102 103 2.5 x 103 1 X 104 103 103 103 103 5 x 103 > 105 > 105
2050/531 103 i03 103 2.5 x 104 i03 103 103 102 105 > 105 > 102
2050/532 102 103 n.d. n.d. 103 i03 102 5 x 103 105 > 105 > 105
2050/534 102 103 5x 103 1 X 104 102 102 103 103 5 x 103 >105 >105
2050/535 102 102 2.5 x 103 1 X 104 102 102 102 102 102 >105 > 1i0
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Figure 2 ELISA for the quantitative evaluation of unbound
bispecific MAb after double anti-idiotype affinity chromato-
graphy. Individual wells contained the antigen amounts (GIT-
mucin = antigen A, a, HSA-benzyl-DTPA-Y-gel, b, indicated on
the abscissa mixed with 200 ng of bispecific MAb BW 494 x
BW 2050 (0) or with 200 ng of irrelevant isotype matched MAb
BW 227 (0). Optical density expressed in mE at the ordinate
represents the amount of unbound MAb in the supernatant at
each individual antigen concentration. At antigen amounts above
500 mg no residual bispecific MAb could be detected in the
supernatants in contrast to the unspecific MAb where essentially
all of the MAb could be refound.
uptake determined after 30' and 24 h. The data are sum-
marised in Table II and show that DTPA-Y-90 is the most
stable of the three chelates investigated. At least 100-fold
more free Y-90 was found in the mineralised part of the bone
24 h after injection of the EDTA-Y and DOTA-Y-90 chelates
than after infection of the DTPA-Y-90 chelate. These in vivo
stability data strongly suggest that DTPA-Y-90 is the
preferable chelate for in vivo application.
Table II Estimation of Y-90 deposition in bone or bone marrow
% ofinjected dose deposited in
Bone marrow Bone
Chelate 30' 24 h 30' 24 h
EDTA-Y-90 0.235 0.003 2.46 1.67
DTPA-Y-90 0.246 0.006 0.161 0.017
DOTA-Y-90 0.314 0.101 2.21 3.95
Discussion
The present report introduces a two phase radioimmuno-
therapy approach which consists of essentially three steps:
(1) A long term binding phase in which a nontoxic bi-
specific anti-GIT-mucin x anti-DTPA-Y (or anti-CEA x
anti-DTPA-Y) MAb penetrates the tumour tissue, binds to
the tumour cells and is retained;
(2) A waiting period of several days in which the non-
specifically bound bispecific MAb is eliminated from the
body or metabolised in the liver parenchymal cells while
the tumour bound MAb remains in the interstitial space or
on the tumour cell membrane;
(3) A short term binding phase in which the radiolabelled
DTPA-Y binds to the new receptor created on the tumour
by the anti-DTPA-Y arm of the bispecific MAb. Unbound
DTPA-Y distributes extracellularly and is eliminated dur-
ing a few minutes via kidneys.
The experimental data generated in this study support the
assumptions made in the first step. We have shown that it is
possible to obtain a significant tissue penetration of solid
human carcinoma xenografts after 10 daily i.v. injections of
high doses of tumour specific MAb. This finding is in con-
trast to reports showing that a single i.v. injection of radio-
labelled MAb leads to binding ofMAb only at the rim of the
tumour (Del Vecchio et al., 1989; Pervez et al., 1988; Ong &
Mathe, 1989). The immunohistochemical methodology applied
in our work allowed an exact localisation of the MAb to the
tumour cell membranes, the interstitial space and the lumen,
i.e. outside the tumour cells. This localisation was observed
at the end of i.v. therapy on day 10 (Figure la) as well as on
day 20 (Figure lb) and on day 30 (Figure Ic). This tissue
penetration and long term retention phase was shown to be
similar to two distinct MAbs, the CEA-specific MAb BW 431
and the GIT-mucin specific MAb BW 494 (Bosslet et al.,
1986, 1988a). Similar results were obtained for an additional
pancreatic adenocarcinoma xenograft system (PaTuII, data
not shown) arguing against a uniqueness of the CoCa4 colon
carcinoma xenograft. Repetitive long term and high dose
injections led therefore in two independent tumour systems to
localisation of MAb at the surface of tumour cells even at
apic'al sites of tumour cells. Despite repeated injection of high
doses of MAb (corresponding to 8 g of MAb/patient) epitope
saturation in the tumour tissue was not obtained (Figure If).
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fragments or genetically engineered domain antibodies (Huse
et al., 1989; Ward et al., 1989).
The second step of our two phase radioimmunotherapy
approach was experimentally proven by Steinstraesser et al.
(1988) who showed that biosynthetically as well as In-111-
labelled MAb is metabolised in the liver parenchymal cells,
i.e. no more accessible from outside.
The efficiency of the third step is highly dependent on the
affinity of the anti-chelate arm of the bispecific MAb for the
chelate metal complex. Therefore we tried to generate high
affinity anti-DTPA-Y MAbs by immunising Balb/c mice with
a specially synthesised highly immunogenic hapten carrier
complex. Immunisation with this HSA-benzyl-DTPA-Y com-
plex resulted in the generation of 350 clones producing MAbs
binding to the immunogen. From these MAbs those which
could be inhibited in their binding to the immunogen by free
DTPA-Y or related compounds were selected (Table I). Out
of these hybridomas, MAb BW 2050/174 was selected
because of its strong binding to DTPA-Y and its excellent
binding to EDTA-Y. Thus this MAb is heteroclitic, binding
more efficiently to EDTA-Y than to DTPA-Y the immunis-
ing hapten. Interestingly, all MAbs binding to DTPA-Y or
EDTA-Y consisted of a IgG, heavy chain and a lambda-light
chain. This is in contrast to all other MAbs generated by the
authors in the Balb/c system which exclusively use a kappa-
light chain.
Using quadroma technology, it was possible to generate a
stable clone producing >20fg of MAb 106 cells 24 h'.
Bispecific MAb could be purified from the quadroma super-
natant using double anti-idiotype chromatography. The
immunoreactivity of this bispecific anti-GIT mucin x anti-
DTPA-Y-90 MAb was greater than 95% for each individual
arm and is exceptionally high when compared to bispecific
MAbs purified by other methods (Doussal et al., 1989; Smith
et al., 1990; Lenz & Weidle, 1990).
Future experiments will be needed to determine whether
the affinity of the single anti-CEA or anti-GIT-mucin arm of
the bispecific MAb is sufficient to enable these reagents to
penetrate and be retained in the tumour as efficiently as the
mono-specific bivalent MAbs. The most critical point in our
approach is probably the affinity of the anti-DTPA-Y arm
for the free DTPA-Y. To be effective this chelate has to bind
very efficiently in vivo to the anti-DTPA-Y arm of the bi-
specific MAb present on the tumour. The small hydrophilic
DTPA-Y should be trapped by the anti-DTPA-Y arm like a
small hormone (Reubi et al., 1987; Krenning et al., 1989) by
its receptor and this should lead to a quick and efficient
localisation to the tumour. However, this is only possible if
the i.v. injected Y-90 chelate is stable in vivo and not non-
specifically trapped in normal tissues. Comparative in vivo
studies in rats using EDTA-Y-90, DTPA-Y-90 and DOTA-
Y-90 showed that because of its stability, the most suitable
chelate for in vivo use is the DTPA-Y-90 chelate. Y-90 levels
in mineralised bone 24h after injection of EDTA-Y-90 or
DOTA-Y-90 were 100-fold higher than after injection of
DTPA-Y-90 (Table II).
The reagents presented in this paper may overcome the
problems of tumour heterogeneity and limited MAb percola-
tion (Jain, 1987; Bosslet et al., 1990) in human tissues. The
long range radiation of Y-90 (9 mm) stably chelated to
DTPA combined with the high avidity bispecific intact MAb
should allow the development of a new and more effective
radioimmunotherapy regimen for carcinomas.
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